Latest Interviews
Showing 1–6 of 6 transcripts.
Clear all filters- a16z19 min
Healthcare Has Left the Building
A structural transformation is dissolving traditional silos between payers, providers, and technology firms to shift care from centralized hospitals to home settings while leveraging mobile diagnostics and AI-driven logistics. Major market entrants are challenging established models through value-based care initiatives and programmed therapies that enable proactive monitoring and personalized treatments like gene editing. This evolution modernizes the medical ecosystem to prioritize patient outcomes and efficiency, though the fundamental human need for care remains the driving force behind these technological accelerations.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z7 min
a16z Podcast | Players and Paths for Healthcare Startups
Healthcare startups navigate a complex, multi-stage landscape by aligning their go-to-market strategies with either therapeutic, diagnostic, or tool-based verticals to overcome distinct regulatory and reimbursement hurdles. Founders must determine whether to pursue internal drug development or leverage non-exclusive licensing for platforms, as seen in the billion-dollar valuation success of Atomab or the industry dominance of Illumina. This approach requires immediately defining specific evidence needs, regulatory pathways, and payment entities to ensure viable product commercialization in a fragmented market.
- a16z15 min
a16z Podcast | Revisiting the Gene
Carlos Araya, Gabe Otte, Jorge Conde
Jungla and Freenome are addressing critical bottlenecks in genomics by replacing static data interpretation with AI-driven models that contextualize variants and analyze dynamic circulating DNA for real-time health monitoring. Despite their ability to improve diagnostic accuracy through iterative learning, these technologies face significant barriers, including a stark disparity between cheap sequencing and expensive interpretation, as well as high reimbursement hurdles that leave 80% of tests uncovered. The industry must also navigate complex legal and ethical risks, exemplified by malpractice cases arising from misinterpreted genetic data, while developing novel payment structures to prove clinical value beyond traditional insurance models.
- a16z17 min
Programming Medicine
The medical field is undergoing a paradigm shift from chemical synthesis to programming living entities like cells, genes, and microbes as direct therapeutics. Four core imperatives—sensing disease, executing treatments, containing activity to specific sites, and self-terminating after success—are now driving the development of advanced therapies such as CAR-T, CRISPR gene editing, and engineered microbiome treatments. This evolution aims to overcome historical safety barriers and treat the thousands of genetic diseases and cancers affecting a significant portion of the global population.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.